Key result
Vasodilator drug treatment for 12 weeks improved treadmill exercise times (P<0.01) but did not improve daily activity pedometer scores (258 vs 261 x 10^2 steps/week) in chronic heart failure.
Why the study?
Does 12 weeks of vasodilator drug treatment improve laboratory exercise capacity and daily customary activity in patients with mild to moderate chronic heart failure?
Observational (n=28)
No
Does 12 weeks of vasodilator drug treatment improve laboratory exercise capacity and daily customary activity in patients with mild to moderate chronic heart failure?
Vasodilator treatment in heart failure improves laboratory exercise capacity but fails to improve daily customary activity as measured by pedometers, highlighting the limitations of conventional exercise tests.
Answers are grounded in this paper and cite their sources.
Lab gains with vasodilators may not translate to daily activity; leaves open treadmill tests as surrogates for real-world function in heart failure.
OBJECTIVES: To examine the effects of drug treatment on laboratory exercise tests in relation to measures of daily activity in patients with chronic heart failure. SETTING: University teaching hospital. SUBJECTS: 18 patients with mild to moderate chronic heart failure (New York Heart Association functional class II-III) and 10 age matched healthy controls. METHODS: Assessments were made before and after 12 weeks of vasodilator drug treatment. Exercise capacity was measured during two different types of treadmill exercise, one using a ramp protocol and the other a fixed work load. Corridor walk tests at three self selected speeds were also undertaken and measures of customary activity assessed from pedometer scores. RESULTS: Exercise times were significantly increased from baseline (P < 0.01) with both treadmill protocols after 12 weeks of drug treatment, with a positive correlation between the duration of treadmill exercise for both protocols (r = 0.69, P < 0.01). Corridor walk tests of 100 m at a self selected slow speed also improved (P < 0.02) but these did not correlate with the changes in treadmill exercise time. The pedometer scores of the patients with heart failure were greatly reduced compared with those of the controls (258 (45) x 10(2) v 619 (67) x 10(2) steps/week, P < 0.001) and after 12 weeks of treatment were unchanged (261 (42) x 10(2) steps/week). CONCLUSIONS: These data confirm the need to use different exercise protocols when assessing the benefits of drug treatment in patients with chronic heart failure. Treatments that seem effective with conventional laboratory based exercise tests may not improve daily activities. This may reflect a failure of apparently successful treatment and should be considered when interpreting clinical trials.
No takes yet. Share an insight, caveat, or question.
Walsh et al. (1995) conducted an observational in chronic heart failure (n=28). vasodilator drug treatment vs. baseline / healthy controls was evaluated on Exercise capacity and daily activity. Vasodilator drug treatment for 12 weeks improved treadmill exercise times (P<0.01) but did not improve daily activity pedometer scores (258 vs 261 x 10^2 steps/week) in chronic heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: